SARS-CoV-2, RSV, Influenza A & B (4 in 1)
PDB ID: 7DWY. Source: RCSB Protein Data Bank. For illustration purposes only.
VeriGoldTM SARS-CoV-2, RSV, Flu A & B
The VeriGold™ SARS-CoV-2, RSV, Influenza A & B Rapid Diagnostic Test is an immunochromatographic assay for the qualitative detection of SARS-CoV-2, Respiratory Syncytial Virus (RSV), Influenza A, and Influenza B viral antigens in human nasal swab specimens. This test is intended to aid in the rapid differential diagnosis of respiratory infections caused by SARS-CoV-2, RSV, Influenza A, and Influenza B, providing results within minutes to support timely clinical decision-making during respiratory illness seasons and outbreak situations.
The test is intended for professional and laboratory use only. Negative results should be interpreted in conjunction with clinical findings and may require confirmation by additional methods, as they do not exclude infection with SARS-CoV-2, RSV, Influenza A, or Influenza B and should not be used as the sole basis for treatment or other patient management decisions.
| Ref. Code | 811028 |
| Analyte | Viral antigens of SARS-CoV-2, RSV, Influenza A, and Influenza B |
| Format | POCT rapid test (cassette / cartridge) |
| Diagnostic Readout | Qualitative |
| Reading Time | 10 minutes |
| Measuring Range | Not applicable |
| Cut-off Value | Not applicable |
| Sensitivity / Specificity | SARS-CoV-2: 96.2% / 98.9%RSV: 96.8% / 99.5%Flu A & B: 97.5% / 99.5% |
| Storage Conditions | 2–30°C |
| Shelf Life | 12 months |
| Certificate | CE |
| Sample Types | Nasal swab |
| Sample Volume | 100 µL (3 drops) of extraction reagent with specimen |
| Collection Method | Nasal swab specimen collection |
| Sample Stability | Stable for testing within 1 hour at room temperature (as validated) |
| Acceptable Anticoagulants | Not applicable |
| Notes on Handling | Specimens should be collected and handled using standard laboratory procedures. Use fresh samples when possible and avoid hemolyzed, lipemic, or contaminated specimens. |
| Detection Method | Immunochromatography |
| Antibody Format | Multiplex / sandwich |
| Signal Generation | Colloidal gold |
| Reading Method | Instrument-based |
| Mechanism | The assay is based on a sandwich immunochromatographic lateral flow principle, in which SARS-CoV-2, Respiratory Syncytial Virus (RSV), Influenza A, and Influenza B viral antigens present in the nasal swab specimen bind to specific labeled antibodies during migration along the membrane by capillary action. The resulting antigen–antibody complexes are captured by immobilized antibodies at distinct test regions specific for SARS-CoV-2, RSV, Influenza A, and Influenza B, forming antibody–antigen–antibody sandwich complexes that produce visible signals indicating the presence of the respective viral antigens in the sample. |
| Tests per Kit | 20 Tests |
| Dimension of Kit Box | 16.5 × 13.5 × 8cm |
| Boxes per Carton | 55 Kits |
| Tests per Carton (Bulk) | 1100 Tests |
| G.W. per Carton (Boxed) | 20 kg |
| G.W. per Carton (Bulk) | 23.6 kg |
| Carton Dimension | 67 × 57.5 × 39 cm |
| Carton Volume | 0.15 CBM |
| Packaging Format | Individual sealed test kits / bulk configuration (as applicable) | Items Included | - 20 test cassettes- 20 extraction solutions- 20 sterile swabs- Instructions for Use |
| Storage & Shipping Conditions | Standard ambient transport; store according to product label requirements |
Let’s advance POCT diagnostics together
Shenzhen Kang Sheng Bao
Biotechnology Co., Ltd.
Second Floor, Block 3, Anda
Electronic Industrial Park,
Fuhai, Bao’an District,
518103 Shenzhen,
Guangdong Province, PRC
+86 0755 27417763
info@ksbbiotech.com